Apellis Pharmaceuticals Inc
(NAS:APLS)
$
28.075
-0.485 (-1.7%)
Market Cap: 3.49 Bil
Enterprise Value: 3.59 Bil
PE Ratio: 0
PB Ratio: 12.94
GF Score: 42/100 Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023 / 04:20PM GMT
Release Date Price:
$92.12
(-1.28%)
Unidentified Analyst
Thanks, everyone, for joining us Day 3 of the Goldman Sachs Global Healthcare Conference. And obviously, we're thrilled to be joined by the team from Apellis Pharmaceuticals. I mean, not a lot going on, so it's kind of show time for you all. I think I'll start with the first question, what's with the hat?
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Yes, I'm a big Boston Red Sox fan now...
Unidentified Company Representative
Boston Soccer fan. That's awesome. Thank you.
Questions & Answers
Unidentified Analyst
Amazing. Excellent. All right. So let's start at a very high level, then we'll kind of dive right into it. Walk us through how the launch of SYFOVRE, you're recently approved drug in geographic atrophy is progressing?
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Thank you so much, [Medwin], and thank you, everyone, for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot